Stephanie Berg, DO
Medical Oncology · Boston, MANPI 1598064750
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Eisai Inc. at 31.8% of the total. Reporting peaked in 2022 at $119,825 and has fallen 84.3% since, to $18,762 in 2025. Among medical oncology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $727.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$59K
- Exelixis Inc.$57K
- E.r. Squibb & Sons, L.L.C.$29K
- Pfizer$10K
- Bristol Myers Squibb$7K
- AstraZeneca$6K
- plus $17K from 15 others
Across 26 payments — averaging $27,111 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$487K
- Seagen Inc.$205K
- E.r. Squibb & Sons, L.L.C.$13K
What the payments were for
- Consulting fees$63,91535%
- Speaking & faculty fees$91,30049%
- Travel & lodging$19,28510%
- Food & beverage$9,8975%
- Education$2660%
- Entertainment$1530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 98 | $58,771 |
| Exelixis Inc. | 76 | $57,311 |
| E.r. Squibb & Sons, L.L.C. | 16 | $28,987 |
| Pfizer | 13 | $10,457 |
| Bristol Myers Squibb | 7 | $6,640 |
| AstraZeneca | 5 | $5,874 |
| Johnson & Johnson | 4 | $4,976 |
| Myovant Sciences Inc. | 3 | $4,038 |
| Seagen Inc. | 5 | $2,547 |
| Sanofi | 1 | $1,812 |
| Janssen Scientific Affairs, LLC | 1 | $1,280 |
| AVEO Pharmaceuticals, Inc. | 9 | $1,097 |
| Gilead | 4 | $320 |
| Incyte Corporation | 3 | $184 |
| Bayer | 1 | $107 |
| Adaptive Biotechnologies Corporation | 1 | $107 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Sumitomo Pharma America, Inc. | 2 | $72 |
| Secura Bio, Inc. | 1 | $59 |
| Merck | 1 | $48 |
| Astellas Pharma US Inc | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$184,816 in reported general payments places this provider in the 90th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 33 | $362,182 |
| NubeqaDarolutamide | 11 | $138,412 |
| OrgovyxRelugolix | 23 | $61,613 |
| Abiraterone Acetate | 30 | $26,140 |
| Prednisone | 24 | $202 |
| Alendronate Sodium | 12 | $61 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $31 | $362,18233 claims |
| BayerNubeqa | $107 | $138,41211 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $72 | $61,61323 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,280 | $26,14030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 medical oncology providers in Massachusetts.
Other medical oncology in Boston
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.